Samir Malkani is an Endocrinology/Metabolic physician affiliated with UMass Memorial Health Care. OpenAlex indexes 38 publications with 1,284 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Lake Ave N
Department Of Endocrinology
Worcester, MA 016550002
Telephone
508-334-3206Provider last certified this registry record 29 Oct 2020.
Clinical trials
- Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Sponsor: University of Massachusetts, Worcester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20221 payment
- Abbott LaboratoriesProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
75.4%Insulin Analog26.4%Lantus Solostar21%Tresiba Flextouch U-10013%Novolog Flexpen13%Humalog Kwikpen U-10010%Basaglar Kwikpen U-1008%Admelog Solostar6%Fiasp Flextouch5%Humalog5%Novolog4%Lantus4%Tresiba Flextouch U-2003%Toujeo Solostar3%Fiasp2%Tresiba2%Insulin Lispro2%Toujeo Max Solostar1%Part D<11 patientsGLP-1 receptor agonist25%Ozempic37%Trulicity33%Mounjaro30%Part D≥110 patients+ 8 more classes in this area
Cardiovascular
13.2%Statin5.7%Atorvastatin Calcium49%Rosuvastatin Calcium31%Simvastatin14%Pravastatin Sodium5%Part D<11 patientsACE inhibitor2.6%Lisinopril100%Part D≥35 patients+ 5 more classes in this area
Hormonal (systemic)
7.4%l-Thyroxine6.5%Levothyroxine Sodium86%Synthroid14%Part D≥69 patientsThyroid Hormone Synthesis Inhibitor0.5%Methimazole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit
Diabetes Technology & Therapeutics
2026 - Management of Continuous Glucose Monitors in Radiation Oncology Patients
Practical Radiation Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Aurigemma, MD
UMass Memorial Health Care
Richard Irwin, MD
UMass Memorial Health Care
Craig Lilly, MD
UMass Memorial Health Care
David Keefe, MD
UMass Memorial Health Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”